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Short Communication
Cross-resistance to cytotoxic drugs in human glioma cell
lines in culture
S. Merry, S.B. Kaye & R.I. Freshney
Department of Clinical Oncology, University ofGlasgow, 1 Horselethill Road, Glasgow G12 9LX, UK.
In several animal tumour models cross-resistance
has been observed between the antibiotic
actinomycin D (AD), the anthracyclines adriamycin
(ADR) and daunorubicin (DNR), the semi-
synthetic podophyllotoxin VP16-213 (VP16) and the
Vinca alkaloids vincristine (VC) and vinblastine
(VBL) (see Table I). Cross-resistance has been
demonstrated both in vitro (Biedler & Riehm, 1970;
Nishimura et al., 1978; Baskin et al., 1981) and in
vivo (Kessel et al., 1968; Dano, 1972; Kaye &
Bowden, 1980; Chitnis et al., 1982; Seeber et al.,
1982) and in general the cross-resistance does not
extend to other drugs.
This phenomenon, known as pleiotropic drug
resistance, is interesting because of the structural
and biological dissimilarity of these drugs. It is
possible that a common mechanism underlies the
emergence of resistance to these compounds which
may have important consequences in the clinical
treatment of cancer using chemotherapy.
Data from human tumours are limited. There are
few clinical data regarding the emergence of
pleiotropic drug resistance, but it is a general
impression that when resistance to a cytotoxic drug
regimen develops clinically, even though it is
possible to identify other regimens which have
short-lived activity, universal drug resistance
usually ensues. However the clinical situation is a
complex one since cytotoxic drugs are generally
given in combination, which makes the recognition
of any particular pattern of cross resistance
unlikely.
Data from human cell lines in culture are also
limited and it remains unclear whether cross-
resistance between antibiotics, anthracyclines,
VP16-213 and Vinca alkaloids is a common finding
in vitro. Beck (1983) has however demonstrated cross-
resistance between Vinca alkaloids, DNR, VP16,
AD and colchicine in a human leukaemic lympho-
blast cell line originally selected for resistance
to VBL. This cell line remained sensitive to podo-
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phyllotoxin, methotrexate and 6-mercaptopurine.
Shoemaker et al. (1983) have also reported
pleiotropic drug resistance in human small cell lung
cancercell linesderived frompatientswithprogressive
disease during combination chemotherapy. In this
case, however, the fact that the tumours had been
treated with drugs in combination means that
different mechanisms of resistance to single agents
may be operative. This situation is therefore
possibly different from that of the animal models
where treatment with a single agent has been shown
to induce resistance to other structurally and
functionally unrelated agents.
There is some difficulty in extrapolating results
obtained from cell lines to the clinical situation.
Human tumours are known to display a
considerable degree of heterogeneity and there are
generally different clonal subpopulations within a
single tumour (Heppner & Shapiro, 1983). Thus it
is conceivable that the chemosensitivity of a cell
line obtained from a tumour may not be
representative of the tumour as a whole.
Nevertheless, the demonstration of pleiotropic drug
resistance in human tumour cell lines would provide
a rational basis for attempts to overcome clinically
observed resistance to specific drugs, e.g.
adriamycin, vinca alkaloids, using a number of
agents, notably calcium antagonists (Tsuro et al.,
1982), which have been shown to be effective in
animal and human tumour cell lines.
In this study we examine the in vitro sensitivity of
six cell lines established from individual cases of
human glioma to AD, ADR, VC, VP-16, 5-
Fluorouracil (5-FU) and L-phenylalanine mustard
(L-PAM). Human glioma cell lines were chosen for
this study because of their relative ease of
culture.
Cell lines were obtained from human glioma as
described previously (Morgan et al., 1983). All the
tumours used were malignant astrocytomas
(Kernohan grade III or IV) confirmed from
paraffin wax section by Prof. D.I. Graham
(Department of Neuropathology, Institute of
Neurological Sciences, Southern General Hospital,
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Table I Cross-resistance to cytotoxic drugs in animal models.
Author Cell Line AD ADR/DNR VP16 VBL/VC
Kessel et al.
(1968) P815 Murine leukaemia ** R R
Biedler & Riehm Chinese hamster
(1970) transformed R R R
Dano
(1972) Ehrlich ascites - R R
Johnson et al.
(1978) P388 R R R R
Nishimura et al. L51787 murine
(1978) lymphoblastoma R R
Kaye & Bowden
(1980) ROS murine sarcoma R R R
Baskin et al. C46 murine
(1981) neuroblastoma R R
Seber et al.
(1982) Ehrlich ascites R R
Chitnis et al.
(1982) L1210 R R
Kartner et al.
(1983) CHO R R
Gupta
(1983) CHO R R R R
*Resistance observed. Where more than one drug appears at the top of the column R
indicates resistance to either or both of the drugs.
**Drug not studied.
Glasgow, U.K.). All the cell lines grew as
monolayers in culture.
The growth medium used for the cell cultures
was Ham's FIO supplemented with Eagle's MEM
non-essential amino acids (Flow Laboratories), 50
unitsml- I benzyl penicillin, 50jugml-1 streptomycin
sulphate and with a gas phase of 5% C02. The
medium was supplemented with 10% foetal bovine
serum (Flow Laboratories).
The drugs used in this study were adriamycin
(Farmitalia Carlo Erba Ltd, Barnet, Herts, U.K.),
actinomycin D (trade name "Lyovac Cosmegen",
Merk Sharp and Dohme International, Rahway,
NJ, U.S.A.), vincristine sulphate (trade name
"Oncovin", Eli Lilly and Co. Ltd, Basingstoke,
U.K.), VP16-213 (trade name "Vepesid", Bristol
Myers Pharmaceuticals, Slough, U.K.), 5-
fluorouracil (Roche Products Ltd, Welwyn Garden
City, U.K.) and L-phenylalanine mustard
(melphalan, trade name "Alkeran", The Wellcome
Foundation Ltd, London, U.K.). They were diluted
according to manufacturers' instructions for
injection and stored at -20°C until required (no
longer than 1 month after freezing). They were then
further diluted in culture medium to the required
concentrations. In the case of L-PAM care was
taken to ensure that these operations were carried
out within 30min because of the instability of the
drug. In no case did the volume of diluent added
with the drug exceed 1% of the final volume.
Radiochemicals were obtained from Amersham
International PLC (Amersham, Bucks, U.K.).
Drug sensitivity assays were carried out using a
modifiaction of a method described previously
(Morgan et al., 1983). Exponentially growing cells
were trypsinised and seeded into 96-well Linbro
microtitration plates to give 103 cells per well. After
3 days medium was removed from the plate by
suction and replaced by fresh drug-free medium.
After a further 24h serial dilutions of the drugs
were added to duplicate wells in the plate. Two
wells of each row were left free of drugs to act as
controls. The drug containing medium was replaced
with fresh drug-containing medium after 24 and
48 h during a total period of exposure to drugs of
72h. The drug-containing medium was then
replaced with drug-free medium and the cells were
allowed a recovery period of 5 days with medium
changes after 3 and 4 days. The viability of cells
remaining in each well was determined by isotopic
precursor incorporation into protein as descibred
below. This technique has been previously
demonstrated to produce equivalent results to
cloning for 5 glioma cell lines (including G-IJK)DRUG RESISTANCE IN HUMAN GLIOMA CELL LINES 833
when treated with 6 drugs including VC and 5-FU
(Morgan et al., 1983).
In all drug experiments, cell counts (using a
model ZB, Coulter Counter) were made of replicate
plates of each cell line to determine population
doubling time and to ensure that the control
cultures remained in exponential growth throughout
the period of drug-treatment and recovery. The
period of drug exposure of 72h exceeded one
population doubling time with all of the cell lines
used in these experiements.
At the end of the experimental cell number was
assayed by exposing the cells to medium containing
31iCiml-1 [35S]-methionine (specific activity 638-
1275 Cimmol-1) or 1ICiml -1 L-4,5-[3H]-leucine
(specific activity 10mCi mol-1) for periods of
between 4j and 24h. During this period the rate of
incorporation of labelled amino acid has been
shown to be linear (Freshney et al., 1975). The
plates were then washed and cell protein
(solubilised in 1 MNaOH) counted as previously
described (Freshney et al., 1975). The incorporation
of labelled amino acid of each well was expressed
as a percentage of the control in that row and the
dose of drug that inhibited protein synthesis by
50% (ID50) determined.
The cell lines are ranked in order of sensitivity
(ID50) to each drug in Table II. Where duplicate
determinations were carried out the mean of the
two values was used to assign the ranking position.
The Table lists the cell lines in order of their
sensitivity to AD and visual inspection of the data
Table II Drug sensitivity of glioma cell lines-ranked
from most sensitive (1) to most resistant (6).
Cell line AD VP16 VC ADR L-PAM 5-FU
G-MCF 1 1 2 1 4 1
G-CCM 2 2 1 4 2 6
G-UVW 3 3 3 2 1 5
G-IJK 4 4 4 5 3 3
G-RM 5 5 5 6 6 4
G-MCN 6 6 6 3 5 2
indicates that there is a good correlation between
the sensitivities of the cell lines for the drugs AD,
VP16 and VC with a partial correlation for ADR
and perhaps for L-PAM. In the case of 5-FU,
however, there is little evidence of co-ordinate
sensitivity with the other five drugs.
Statistical analysis of the data was carried out
using Kendall's coefficient of concordance (W)
(Siegel, 1956). The null hypothesis is that there is
no correlation between the ranking of sensitivity for
the six cell lines. The value of W for the entire table
is 0.5 (P<0.01) and although this value is highly
significant it can be improved to 0.7 by the
exclusion of 5-FU from the calculations, to 0.8 by
the exclusion of L-PAM and 5-FU, and 1.0 by the
exclusion of ADR, L-PAM and 5-FU. These results
confirm the apparent relationship between the
sensitivities of the cell lines to AD, VP16 and VC.
Table III shows the complete results of our drug-
sensitivity experiments. Where duplicate
determinations were carried out the range of values
obtained is shown. The duplicate values shown for
(a) cell line G-UVW drug ADR, (b) cell line G-
MCF drug L-PAM and (c) cell line G-IJK drug
L-PAM represent duplicates in which labelling was
carried out using [3H]-leucine and [35S]-methionine
in the different experiments. The ranges of the
duplicates obtained in these cases (i.e. 1.2 to 3-fold)
do not appear to be significantly greater than the
ranges obtained where labelling was carried out
with a single agent (i.e. cell line G-RM drugs AD,
VP16, ADR and 5-FU- ranges 1.2 to 2.4-fold) and
so the choice of labelling agent appears not to be
crucial.
Some comment should be made on the observed
variability of the data in terms of the ranking order
of the cell lines. While in no case would a 3-fold
variation in IDSO alter the ranking order of the
most sensitivie and most resistant cell lines such a
variation would have an impact on the middle of
the ranking order. To assess the effects of such
experimental error Table IV was derived from
Table II. Here cell lines having ID50 values which
lie within a 2.7-fold range are assigned the mean
Table III Cytotoxicity data.
ID50 ofcylotoxic drugs
Population
Passage doubling AD VP16 VC ADR L-PAM 5-FU
Cell line no. time (h) (x J'-10M)(x 10-7M)(x10-9M)(x 10-8M) (x 10-6M) (x 10-6M)
G-MCF 4 52 6 3 100 6 50-60 5
G-CCM 30 59 70 30 6 60 3 170
G-UVW 20 58 120 10 150 20-60 1 150
G-IJK 8 71 140 180 170 90 10-25 10
G-RM 6 68 100-200 500-1200 180 450-550 250 25-30
G-MCN 3 67 150-300 1900 30,000 50 220-250 8834 S. MERRY et al.
Table IV Drug sensitivity of glioma cell lines-ranked as
in Table II, i.e. from most sensitive (1) to most resistant
(6)-with values which lie within 2.7-fold range assigned
the mean of their values.
Cell line AD VP16 VC ADR L-PAM 5-FU
G-MCF I 1 1 1 4 2
G-CCM 3.5 2 3.5 3.5 2 5.5
G-UVW 3.5 3.5 3.5 3.5 1 5.5
G-IJK 3.5 3.5 3.5 3.5 3 2
G-RM 3.5 5.5 3.5 6 5.5 4
G-MCN 6 5.5 6 3.5 5.5 2
value of their rankings in Table II (Siegel, 1956).
The 2.7-fold range was chosen as the figure
approximates the maximum variation obtained in
duplicate experiments and was also the largest value
which enabled the data to be divided into discrete
groups with no overlap. In this case the values of
W (corrected for the presence of tied observations,
Siegel, 1956) are 0.4 (P<0.05) for the whole table,
0.6 (P<0.05) when 5-FU is excluded from the
calculations, 0.7 (P=0.05) when L-PAM and 5-FU
are excluded and 0.8 (P<0.05) when ADR, L-PAM
and 5-FU are excluded. These results show the
same general trend as described either from Table
II although the statistical signifiance is not as great.
Even when the results are treated in this manner,
however, a statistically significant correlation is
demonstrated between the sensitivities of the 6 cell
lines to AD, VP16, VC and ADR.
Table III also shows the population doubling
times of the cell lines. The variation is small, but
there is a tendency for the slowest growing cell lines
to be the most resistant to the drugs AD, VP16,
VC and ADR. However, while cell kinetic
differences may play a part in the middle of the
ranking table (where differences in sensitivity are
not great), the observed total variations in drug
sensitivity cannot realistically be attributed to this
cause.
Table III also shows the passage number of the
cultures at the time of the drug sensitivity assays. It
can be seen that four of the 6 cultures were at least
6 passages from the primary culture and 2 of the
cultures could be regarded as established cell lines.
The data obtained may therefore not be
representative of the original tumours and for this
reason no attempt was made to correlate the results
obtained with clinical data from the patients.
Furthermore, none of the drugs tested with the
exception of VC and possibly VP16 has
demonstrated appreciable therapeutic benefit in the
treatment of malignant glioma either as single
agents or in combination.
It can be noted from Table III, however, that the
cell lines G-MCF and G-MCN (which were only 4
and 3 passages old respectively) did demonstrate a
wide range in sensitivity to the drugs VC (300-fold)
and VP16 (633-fold). Clinically achievable peak
plasma concentrations are generally 0.1 1 -IM for
VC (Sethi et al., 1981) and 7-701iM for VP16
(Creaven, 1982). These are comparable with the
ranges of ID50 observed, i.e. 0.1-30 uM for VC
and 0.3-190,uM for VP16. These data may
mean that differences in sensitivity observed in the
clinic may have as their basis differences in sensitivity
at the cellular level. However, many other
explanations are possible and furthermore our in
vitro data obtained using a relatively long exposure
to a relatively constant drug concentration may not
be relevant to the clinical situation where there are
both rapidly changing levels of drug and the
potential for metabolism outside the tumour cells.
Our results do, however, demonstrate that cell
cultures derived from human glioma exhibit the
same general pattern of cross-resistance to the
drugs AD, VP16, VC and ADR as is observed in
human haemopoietic cell lines (Beck, 1983) and
possibly small cell lung cancer cell lines (Shoemaker
et al., 1983), and both in vitro and in vivo in animal
tumour models (Table I). This suggests that one
factor underlying the development of resistance to
these drugs by human tumours may be defective
membrane transport (possibly enhanced drug
efflux) as has been postulated as a major factor
responsible for the development of pleiotropic drug
resistance in experimental tumours. However, other
mechanisms such as morphological or kinetic
factors may clearly be operative in the clinical
situation which is a much more complex one.
Nevertheless, further studies aimed at assessing the
role of membrane transport and evaluating means
for circumventing resistance, such as the use of the
calcium antagonists (Tsuro et al., 1982) are
indicated in human solid tumour cell lines and
these are in progress. Our studies on pleiotropic
drug resistance are currently directed to models of
human lung cancer, rather than glioma. The
eventual aim is to translate the laboratory studies
into clinical trials and for this purpose human lung
cancer is a more suitable model.
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